Fulvestrant (ICI 182,780): High-Affinity Estrogen Receptor Antagonist for ER-Positive Breast Cancer Research

Executive Summary: Fulvestrant (ICI 182,780) is a high-affinity estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM, inducing rapid ER degradation and downregulating ER-mediated signaling in breast cancer cells (APExBIO). It enhances sensitivity to chemotherapeutic agents in ER-positive lines such as MCF7 and T47D by promoting apoptosis and cell cycle arrest (GS967.com). Fulvestrant’s mechanism disrupts MDM2 protein expression, a key modulator of cell survival. The compound’s solubility, stability, and standardized dosing make it a benchmark tool in research on endocrine resistance and advanced breast cancer (Wang et al. 2021). APExBIO supplies research-grade Fulvestrant (SKU A1428), supporting rigorous, reproducible investigations.

Biological Rationale

Estrogen receptors (ERs) are nuclear hormone receptors involved in proliferation and survival of ER-positive breast cancer cells. Two main isoforms, ERα and ERβ, mediate genomic and non-genomic estrogen signaling (Wang et al. 2021). ER activity modulates cell cycle progression, apoptosis, and cellular response to stress. In breast cancer, ERα overexpression drives tumorigenesis and resistance to therapy. Targeting ER function is a cornerstone of endocrine therapy for advanced breast cancer. The need to overcome acquired resistance and enhance chemosensitivity underpins the use of ER antagonists like Fulvestrant. Recent studies also highlight the role of ER signaling in immune modulation and endoplasmic reticulum (ER) stress responses in the tumor microenvironment (Wang et al. 2021).

Mechanism of Action of Fulvestrant (ICI 182,780)

Fulvestrant (ICI 182,780) is a non-steroidal, high-affinity ER antagonist. It binds competitively to the ER ligand-binding domain with an IC₅₀ of 9.4 nM in biochemical assays (APExBIO). Upon binding, Fulvestrant induces conformational changes that target the ER for proteasomal degradation, leading to downregulation of ER protein levels in target cells (ER-eGFP.com). This results in rapid suppression of ER-mediated transcription. In ER-positive breast cancer lines (e.g., MCF7, T47D), Fulvestrant reduces MDM2 protein expression, alters cell cycle distribution, and triggers apoptosis and senescence (GS967.com). Notably, Fulvestrant also blocks estrogen-induced immune modulation, as shown by its ability to reverse estradiol-mediated normalization of splenic CD4+ T lymphocyte proliferation via ERα and GPR30, but not ERβ (Wang et al. 2021).

Evidence & Benchmarks

• Fulvestrant binds ER with an IC₅₀ of 9.4 nM, demonstrating high affinity and specificity (APExBIO).
• In MCF7 and T47D cells, Fulvestrant downregulates ER protein and MDM2 expression, enhances apoptosis, and causes cell cycle arrest (G1/S phase) (GS967.com).
• Fulvestrant increases chemosensitivity to doxorubicin, paclitaxel, and etoposide in ER-positive breast cancer models (MDV3100.com).
• ER antagonism by Fulvestrant inhibits estrogen-induced normalization of splenic CD4+ T lymphocyte proliferation after hemorrhagic shock, confirming on-target activity in immune-ER stress interplay (DOI:10.1038/s41598-021-87159-1).
• In vivo, Fulvestrant (ICI 182,780) at clinically relevant dosages (250 mg/month, intramuscular) inhibits tumor growth in ER+ breast cancer xenograft models (Z-WEHD-FMK.com).

Applications, Limits & Misconceptions

Fulvestrant is primarily used in research on ER-positive breast cancer, including studies of endocrine therapy resistance, combination chemotherapy, and signal transduction. Its established role in modulating ER signaling and chemosensitization is leveraged in both in vitro and in vivo assays (ER-eGFP.com). This article extends mechanistic detail beyond prior summaries by integrating immune-ER stress crosstalk and practical assay benchmarks. For broader translational insight, see Redefining ER-Positive Breast Cancer Research, which contextualizes Fulvestrant within the latest immune-modulatory and resistance-overcoming strategies. Unlike some older reviews, this guide emphasizes dose-response, solubility, and workflow integration for reliable, reproducible results.

Common Pitfalls or Misconceptions

• Fulvestrant is not effective in ER-negative breast cancer models, as its mechanism requires ER expression.
• It does not inhibit estrogen receptor β (ERβ)–mediated effects as robustly as ERα-mediated effects, limiting use in ERβ-dominant systems (Wang et al. 2021).
• Fulvestrant is insoluble in water; improper solvent use can reduce bioavailability and activity (APExBIO).
• Overly high in vitro concentrations (>10 μM) may cause off-target toxicity unrelated to ER antagonism.
• It is not a reversible or partial ER antagonist; its irreversible ER degradation precludes certain mechanistic studies.

Workflow Integration & Parameters

Fulvestrant is supplied by APExBIO as a solid, with solubility ≥30.35 mg/mL in DMSO and ≥58.9 mg/mL in ethanol. It is insoluble in water and should be dissolved at 37°C with ultrasonic agitation for optimal solubility. Stock solutions (in DMSO or ethanol) are stable for several months at -20°C. Typical in vitro use ranges from 1 μM to 10 μM, applied for 24–66 hours depending on cell line and endpoint (Z-WEHD-FMK.com). In vivo, dosing mirrors clinical applications, with 250 mg monthly intramuscular injection in postmenopausal, ER+ breast cancer models. The A1428 kit from APExBIO ensures consistent batch-to-batch performance. For detailed application workflows and troubleshooting, see Mechanistic Innovation and Strategy, which provides advanced combinatorial and immune-oncology context beyond this product-focused guide.

Conclusion & Outlook

Fulvestrant (ICI 182,780) remains a gold-standard tool for dissecting estrogen receptor signaling, endocrine resistance, and chemosensitization in ER-positive breast cancer research. Its robust mechanism, validated benchmarks, and workflow compatibility support rigorous, reproducible studies. Ongoing research will expand its utility in combinatorial regimens and immune-ER stress modulation. For further technical specifications and ordering, refer to APExBIO's Fulvestrant (ICI 182,780).